Cassava Sciences Inc(SAVA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Current Price

$41.43

RSI

42.539

Beta:

1.174296

March 23, 2021
293K
-3.7M

-72.691 %
-79.892 %

$0
$0
$0
$0
$0
$0
%
%
%
%
0.000 %

$-6,334,000
$-4,631,000
$-6,557,000
$-11,911,000
$-14,850,000
$-14,145,000
-26.887 %
41.589 %
81.653 %
24.675 %
-4.747 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.